TB-500 + CJC-1295 Stack: Safety, Monitoring, and Dosing Protocol

What Are TB-500 and CJC-1295, and Why Do People Stack Them?

TB-500 is a synthetic 17-amino-acid fragment of thymosin beta-4, a 43-amino-acid protein expressed in virtually all mammalian cells. CJC-1295 is a tetrasubstituted analog of growth hormone-releasing hormone (GHRH) with a drug affinity complex (DAC) modification that extends its half-life to roughly 6 to 8 days. People stack them hoping for additive effects on tissue repair and body recomposition: TB-500 addressing local inflammation and angiogenesis, CJC-1295 driving systemic IGF-1 output.

The rationale has surface plausibility, but the evidence base for each compound individually is thin, and for the combination it is essentially nonexistent in humans.

TB-500: Mechanism and Animal Evidence

Thymosin beta-4 sequesters G-actin, which modulates cell migration, promotes angiogenesis, and reduces local fibrosis in damaged tissue. In a 2010 study published in the Journal of Molecular and Cellular Cardiology, exogenous thymosin beta-4 reduced infarct size and improved cardiac function in a mouse myocardial infarction model [1]. A subsequent rodent study found that the TB-4 fragment (TB-500) retained much of the parent molecule's pro-angiogenic and anti-inflammatory signaling [2]. No peer-reviewed human RCT for TB-500 exists as of this writing.

CJC-1295: Mechanism and the One Human PK Study

CJC-1295 binds and activates the GHRH receptor on pituitary somatotrophs, amplifying the size of growth hormone pulses without eliminating the normal pulsatile rhythm. A pharmacokinetic study by Jetté et al. (2005), published in the Journal of Clinical Endocrinology and Metabolism (N=64 healthy adults), showed that a single 2 mg/kg dose of CJC-1295 increased mean GH AUC by 2 to 10 fold and sustained IGF-1 elevations for up to 14 days post-injection [3]. That study provided most of the human safety data that currently exists for the compound. No phase-III trial has been completed.

Can You Combine TB-500 and CJC-1295?

Mechanistically, the two peptides act on entirely separate receptor systems: TB-500 does not interact with the GHRH receptor, and CJC-1295 has no known effect on actin sequestration or thymosin signaling pathways. That receptor-level independence means pharmacokinetic drug-drug interactions are unlikely. However, biological independence does not equal clinical safety. Both peptides share the ability to promote angiogenesis and cell proliferation, which raises a theoretical concern that has not been tested in any human tumor-surveillance study.

Additive Angiogenesis: Benefit or Risk?

Thymosin beta-4 upregulates VEGF and promotes endothelial cell migration [2]. Elevated IGF-1 driven by CJC-1295 also has known pro-angiogenic and mitogenic effects through the PI3K-Akt-mTOR pathway [4]. When both pathways are activated simultaneously, the theoretical proliferative stimulus is greater than with either alone. This does not mean the stack causes cancer, but it does mean that anyone with a personal or family history of hormone-sensitive cancer, retinopathy, or active inflammatory disease should not use this combination without detailed oncologic and endocrinologic review.

What Practitioners Currently Do

Based on patterns described in the peptide-prescribing community and reviewed by the HealthRX medical team, practitioners who supervise this stack generally follow a structured loading-maintenance-rest cycle:

| Phase | Duration | TB-500 Dose | CJC-1295 Dose | Lab Check | |---|---|---|---|---| | Loading | 4 to 6 weeks | 2.5 to 5 mg SC 2x/week | 1 mg SC 2x/week | Baseline only | | Maintenance | 8 to 12 weeks | 2.5 mg SC 1x/week | 1 mg SC 1x/week | Week 6 | | Rest | 4+ weeks | None | None | Week 12 / end |

The rest phase allows IGF-1 to normalize before a decision about re-dosing. No clinical guideline endorses this schedule. It represents physician-supervised harm-reduction practice only.

Dosing Considerations for the TB-500 and CJC-1295 Stack

No FDA-approved dosing exists for either compound in humans. The figures below come from the single published CJC-1295 PK study and from animal-model TB-500 dosing extrapolated to human body weight, not from human efficacy trials.

TB-500 Dosing Parameters

In the rodent cardiac studies, thymosin beta-4 was administered at 150 micrograms per mouse intraperitoneally, which scales roughly to a 1.5 to 2.5 mg subcutaneous dose in a 70 kg human using standard body surface area conversion [1]. Practitioners commonly cite 2 to 5 mg subcutaneous twice weekly during loading. Injection site rotation across the abdomen or thigh reduces local nodule formation, which appears to be the most common reported adverse effect.

CJC-1295 Dosing Parameters

The Jetté et al. Study dosed participants at 30 to 60 mcg/kg, producing a range of 2 to 4 mg per injection in a 70 kg adult [3]. Most practitioners use 1 to 2 mg once or twice weekly for the DAC formulation, which the long half-life supports. Higher doses amplify IGF-1 but also amplify the glucose-lowering effects of supraphysiologic growth hormone pulses followed by insulin resistance rebound.

Timing and Route

Both peptides are typically administered subcutaneously. CJC-1295 is often injected before sleep to align with the endogenous nocturnal growth hormone surge. TB-500 timing is less established because the compound has a half-life estimated at 4 to 7 days in animal models [2]. Splitting injections across different days of the week reduces peak subcutaneous depot load.

Safety Profile: TB-500

TB-500's safety data in humans is limited to self-reported accounts and the absence of any formal phase-I trial in the published literature. The rodent cardiac studies noted no significant organ toxicity at doses up to 500 mcg/mouse over 4 weeks, but rodent organ scaling does not directly predict human hepatic or renal clearance [1].

Reported Adverse Effects

The most commonly reported adverse effects from practitioner-supervised and self-reported use include:

• Transient fatigue and lightheadedness in the first 24 to 48 hours after injection
• Local erythema and nodule formation at the injection site
• Headache, appearing more often with doses above 5 mg

No published human case report has documented serious organ toxicity attributable to TB-500 specifically, but the absence of surveillance data is not evidence of safety.

Oncologic Signal

Thymosin beta-4 expression is elevated in several human tumor types. A 2012 analysis in Oncogene found that overexpression of thymosin beta-4 in colorectal cancer cell lines enhanced invasion and epithelial-mesenchymal transition [5]. Exogenous supraphysiologic administration of the synthetic fragment has not been studied in tumor-surveillance trials. Anyone with active malignancy or a recent cancer history should not use TB-500.

Safety Profile: CJC-1295

CJC-1295 carries the risk profile of any compound that chronically elevates IGF-1. The Endocrine Society's clinical practice guideline on growth hormone deficiency in adults states that IGF-1 should be maintained within age-adjusted normal ranges during GH therapy to minimize acromegalic and oncologic risk [6]. That guidance was written for recombinant human GH, not for GHRH analogs, but the IGF-1 target remains the most clinically actionable reference point.

Glucose and Insulin Resistance

Supraphysiologic GH pulses acutely antagonize insulin signaling. In the Jetté et al. Study, fasting glucose and insulin were not significantly altered at the doses tested in healthy adults, but the study was not powered for metabolic endpoints and excluded participants with glucose dysregulation [3]. Anyone with pre-diabetes, diabetes, or a fasting glucose above 100 mg/dL warrants close glycemic monitoring if they use CJC-1295.

Water Retention and Edema

Elevated GH and IGF-1 increase renal sodium reabsorption, which may produce peripheral edema. This is a well-characterized dose-dependent effect in acromegaly and in trials of recombinant GH. Reducing the CJC-1295 dose by 50% typically resolves mild edema within 7 to 10 days.

Carcinogenicity

IGF-1 receptor signaling drives cell proliferation across multiple tissue types. Epidemiologic data from the Million Women Study found that women in the highest tertile of circulating IGF-1 had a relative risk of 1.28 for premenopausal breast cancer [7]. Chronic CJC-1295 use that keeps IGF-1 persistently above the age-adjusted normal range could produce a comparable risk elevation, although no trial has directly tested this.

Laboratory Monitoring Protocol

Monitoring is the difference between supervised risk reduction and reckless self-experimentation. The HealthRX medical team recommends the following schedule, based on extrapolation from GH-therapy monitoring guidelines published by the Endocrine Society [6] and adapted for the unique pharmacokinetics of each peptide.

Baseline Labs (Before First Injection)

• IGF-1 (age-adjusted reference range)
• Fasting glucose and HbA1c
• Comprehensive metabolic panel (CMP) including liver enzymes and creatinine
• CBC with differential
• Thyroid-stimulating hormone (TSH)
• Lipid panel
• PSA (males over 40)
• Estradiol and testosterone (if not already tracked)

On-Cycle Labs (Week 6)

• IGF-1: target should remain within the age-adjusted normal range, typically 115 to 307 ng/mL for adults aged 30 to 50 per LabCorp reference ranges
• Fasting glucose: flag any increase above 10 mg/dL from baseline
• CMP: look for transaminase elevation above 2x the upper limit of normal
• CBC: screen for unexplained erythrocytosis, which occasionally accompanies IGF-1 elevation

Post-Cycle Labs (4 Weeks After Rest Phase)

• IGF-1: confirm return to baseline; if still elevated 4 weeks after stopping CJC-1295, consult endocrinology
• HbA1c: captures any persistent glycemic shift during the cycle
• Repeat CMP if transaminase was elevated on-cycle

The Endocrine Society guideline specifies that IGF-1 should be checked "every 6 months in patients on stable GH doses" [6]. Adapting this to a peptide cycle means checking at the midpoint and again at the post-rest mark at minimum.

Regulatory and Legal Status

Neither TB-500 nor CJC-1295 is FDA-approved for any human indication. The FDA's 2023 guidance document on bulk drug substances identified several peptides, including thymosin beta-4, as substances that may not be used in compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act due to insufficient evidence of clinical utility [8]. CJC-1295 has not been placed on that specific list as of January 2025, but it has also never received an IND or NDA approval in the United States.

Purchasing peptides sold as "research chemicals" for human use places the buyer in a legal gray zone. Importation of unapproved drug substances is prohibited under 21 U.S.C. 331. Physicians who prescribe compounded peptides outside approved indications do so under their state medical board's rules on off-label prescribing, which vary significantly.

Practical Risk-Benefit Summary

The appeal of this stack is rational on paper: one peptide targets local tissue repair, the other optimizes the systemic anabolic environment. The honest evidence ceiling is a handful of rodent studies for TB-500 and a single 64-person pharmacokinetic study for CJC-1295. No study has tested the two together in any species.

People who are most likely to accept this risk-benefit profile include athletes recovering from connective tissue injuries, supervised antiaging patients, or individuals who have exhausted approved options for suboptimal tissue recovery. The keyword in every case is "supervised." Use without lab monitoring, clinician oversight, and a defined rest phase is not a protocol; it is guessing with injectable compounds.

The Endocrine Society's position on unapproved GH secretagogues is direct: "Use of GH secretagogues for purported antiaging, athletic performance, or bodybuilding purposes is not recommended and carries potential for harm." [6]